Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment

Drug resistance is a major impediment to the success of cancer treatment. Resistance is typically thought to arise through random genetic mutations, after which mutated cells expand via Darwinian selection. However, recent experimental evidence suggests that the progression to drug resistance need not occur randomly, but instead may be induced by the treatment itself, through either genetic changes or epigenetic alterations. This relatively novel notion of resistance complicates the already challenging task of designing effective treatment protocols. To better understand resistance, we have developed a mathematical modeling framework that incorporates both spontaneous and drug-induced resistance. Our model demonstrates that the ability of a drug to induce resistance can result in qualitatively different responses to the same drug dose and delivery schedule. We have also proven that the induction parameter in our model is theoretically identifiable, and proposed an in vitro protocol which could be used to determine a treatment’s propensity to induce resistance.

[1]  Claude Preudhomme,et al.  Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. , 2003, Seminars in hematology.

[2]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.

[3]  W P Lee,et al.  The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. , 1993, Cancer letters.

[4]  Mina J Bissell,et al.  The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[6]  Fei Li,et al.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients , 2015, PloS one.

[7]  D. T. Birtwistle Introduction to Mathematical Control Theory , 1976 .

[8]  Vittorio Cristini,et al.  Understanding Drug Resistance in Breast Cancer with Mathematical Oncology , 2014, Current Breast Cancer Reports.

[9]  M. Gottesman,et al.  The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .

[10]  H. Ohdan,et al.  Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma , 2016, Cancer medicine.

[11]  Alexander Lorz,et al.  Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.

[12]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[13]  J H Goldie,et al.  A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.

[14]  Franziska Michor,et al.  Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia , 2011, PloS one.

[15]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[16]  R. Wood,et al.  DNA polymerases and cancer , 2011, Nature Reviews Cancer.

[17]  S. Menchón The Effect of Intrinsic and Acquired Resistances on Chemotherapy Effectiveness , 2015, Acta Biotheoretica.

[18]  Mahmood Rasool,et al.  Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era , 2013, PloS one.

[19]  Zahra Aminzare,et al.  Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model , 2014, 1412.0780.

[20]  W. Pao,et al.  Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.

[21]  Shannon M. Mumenthaler,et al.  Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors , 2012, Evolutionary applications.

[22]  D. Waxman,et al.  Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. , 2015, Cancer letters.

[23]  J. Turchi,et al.  Chemotherapy induced DNA damage response , 2013, Cancer biology & therapy.

[24]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[25]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Lu,et al.  Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model , 2013, Acta Pharmacologica Sinica.

[27]  Krutiakov Vm [Eukaryotic error prone DNA polymerases: suggested roles in replication, repair and mutagenesis]. , 2006 .

[28]  Joel s. Brown,et al.  Evolutionary dynamics in cancer therapy. , 2011, Molecular pharmaceutics.

[29]  Mitra Shojania Feizabadi Modeling multi-mutation and drug resistance: analysis of some case studies , 2017, Theoretical Biology and Medical Modelling.

[30]  Cécile Carrère,et al.  Optimization of an in vitro chemotherapy to avoid resistant tumours. , 2017, Journal of theoretical biology.

[31]  C. Blank,et al.  Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.

[32]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[33]  Richard F. Kefford,et al.  Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.

[34]  N. Makridakis,et al.  Translesion DNA Polymerases and Cancer , 2012, Front. Gene..

[35]  R. Golsteyn,et al.  Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells , 2014, International journal of molecular sciences.

[36]  Robert A Gatenby,et al.  Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy , 2012, Physical biology.

[37]  H M Byrne,et al.  A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.

[38]  Robert A Gatenby,et al.  A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.

[39]  Martin A. Nowak,et al.  Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..

[40]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[41]  Gábor E. Tusnády,et al.  A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.

[42]  K. Hirota,et al.  Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers , 2014, PloS one.

[43]  S. Wong,et al.  Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Martin A. Nowak,et al.  A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity , 2015, Nature.

[45]  Gerald J. Fetterly,et al.  Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia , 2013, The AAPS Journal.

[46]  Katarzyna A Rejniak,et al.  Limiting the Development of Anti-Cancer Drug Resistance in a Spatial Model of Micrometastases , 2016, bioRxiv.

[47]  Aleksandra Karolak,et al.  Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. , 2016, Advances in experimental medicine and biology.

[48]  Amy Brock,et al.  Non-Darwinian dynamics in therapy-induced cancer drug resistance , 2013, Nature Communications.

[49]  Joseph M. Negri,et al.  The role of tumour–stromal interactions in modifying drug response: challenges and opportunities , 2013, Nature Reviews Drug Discovery.

[50]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Roberto Chignola,et al.  Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology , 2005, IEEE Transactions on Biomedical Engineering.

[52]  F. Michor,et al.  Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.

[53]  Anna Sótér,et al.  Two-photon laser spectroscopy of antiprotonic helium and the antiproton-to-electron mass ratio , 2011, Nature.

[54]  M. Nowak,et al.  Evolution of resistance to cancer therapy. , 2006, Current pharmaceutical design.

[55]  V. Krutyakov Eukaryotic error-prone DNA polymerases: The presumed roles in replication, repair, and mutagenesis , 2006, Molecular Biology.

[56]  Sarah A Heerboth,et al.  Drug Resistance in Cancer: An Overview , 2014, Cancers.

[57]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[58]  B. Perthame,et al.  Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies , 2012, 1207.0923.

[59]  S. Shackney,et al.  Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. , 1978, Annals of internal medicine.

[60]  B. Perthame,et al.  Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[61]  Doron Levy,et al.  The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[62]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[63]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[64]  Lurias,et al.  MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .

[65]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[66]  William Pao,et al.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.

[67]  Martin A Nowak,et al.  Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers , 2014, Proceedings of the National Academy of Sciences.

[68]  Nicolas André,et al.  Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.

[69]  M. Gottesman,et al.  The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[70]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[71]  A. Pisco,et al.  Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.

[72]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[73]  Georgios D. Mitsis,et al.  Mathematical Modeling of Tumor Growth, Drug-Resistance, Toxicity, and Optimal Therapy Design , 2014, IEEE Transactions on Biomedical Engineering.

[74]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[75]  Claire J. Tomlin,et al.  A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations , 2016, 2016 IEEE 55th Conference on Decision and Control (CDC).

[76]  Franziska Michor,et al.  Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. , 2017, Cancer research.

[77]  J. Nyce,et al.  Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. , 1997, Mutation research.

[78]  D. Axelrod,et al.  Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study , 2017, Cancer Chemotherapy and Pharmacology.

[79]  Y. Erdi Limits of Tumor Detectability in Nuclear Medicine and PET , 2012, Molecular imaging and radionuclide therapy.

[80]  Urszula Ledzewicz,et al.  Drug resistance in cancer chemotherapy as an optimal control problem , 2005 .

[81]  Eduardo D. Sontag Dynamic compensation, parameter identifiability, and equivariances , 2017, PLoS Comput. Biol..

[82]  Lena E Friberg,et al.  Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.

[83]  Christopher P Austin,et al.  A dual-fluorescence high-throughput cell line system for probing multidrug resistance. , 2009, Assay and drug development technologies.

[84]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[85]  Dominik Wodarz,et al.  Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. , 2007, Theoretical population biology.

[86]  Larry Norton,et al.  Log-Kill Hypothesis , 2015 .

[87]  L. Loeb,et al.  Errors in DNA replication as a basis of malignant changes. , 1974, Cancer research.

[88]  Urszula Ledzewicz,et al.  A 3-Compartment Model for Chemotherapy of Heterogeneous Tumor Populations , 2015 .

[89]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.